ClinicalTrials.gg
CompletedNCT01889862Prism-2Updated May 21, 2021Results posted

Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU

A Phase 3 interventional study of BMN165 20mg/day and BMN165 40mg/day in Phenylketonuria (PKU), sponsored by BioMarin Pharmaceutical. Completed at 29 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-05-21.

Sponsored by BioMarin Pharmaceutical · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
215
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing pegvaliase in Phenylketonurias — 1 open to participants now, 2 under way, 1 of them phase 3. pegvaliase · Phenylketonurias.

Enrollment
2nd of 10
215 · median 39
Started
2013
with 1 other
Phase 3
4 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
10 of 10
BioMarin Pharmaceutical

Among the 10 studies testing pegvaliase in Phenylketonurias, this one is the 2nd largest by enrollment, is one of 2 that started in 2013, is one of 4 in phase 3, and was the 7th registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

1 of the 10 studies testing pegvaliase in Phenylketonurias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegvaliase

pegvaliase: first FDA approval 2018 (PALYNZIQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing pegvaliase in Phenylketonurias, or all of them as a file.
02

Study summary

The BMN 165 clinical development program has been designed to demonstrate the safety and efficacy of BMN 165 in reducing blood Phe concentrations in adults with PKU.

Read the detailed description

165-302 is a Phase 3, 4 Part, Randomized, Double-Blind, Placebo-Controlled, Discontinuation Study to Evaluate the Efficacy and Safety of Self Administered Subcutaneous Injections of BMN 165 by Adults With PKU.

This study is open only to adults who have been exposed to BMN165 in a previous study.

Study BMN 165-302 is a four-Part, Phase 3 study.

  • Part 1: Open-label period
  • Part 2: A Randomized, double-blind, placebo-controlled period of 8 weeks
  • Part 3: Two sub-Parts to Part 3:- Part 3A - BMN 165 administered using vial and syringe during this open label period. Part 3B - BMN 165 administered using prefilled syringe during this open-label period.
  • Part 4: A long-term, open-label extension period.
03

Conditions studied

  • Phenylketonuria (PKU)

Browse trials for

Keywords

  • PKU
  • PEG-PAL
  • Prism
  • BioMarin
  • rAvPAL-PEG
  • BMN165
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Individuals eligible to participate in this study must meet all of the following criteria:

  • Have completed a prior BMN 165 study (PAL-003, 165-205, or 165-301) prior to screening
  • Have had a stable BMN 165 dose regimen for at least 14 days prior to screening
  • Are at least 18 y/o and no older than 70 y/o at screening

    • Subjects who are \< 18 y/o and are already enrolled into Study 165-301 under Amendment #1 (10JAN2014) may enroll into this study
  • Has identified a person who is > 18 y/o who has the neurocognitive and linguistic capacities to comprehend and complete the Profile of Mood States (POMS)-Observer rated scale
  • Has identified a competent person(s) > 18 y/o who can observe the subject during study drug administration at certain points in the study

    • A home healthcare nurse may perform the study drug observations
  • Are willing and able to provide written, signed after the nature of the study has been explained and prior to any research-related procedures; for minors, parent or guardian provides written consent and assent may be requested
  • Are willing and able to comply with all study procedures
  • For females of , a negative pregnancy test at screening and willing to have additional pregnancy tests during the study
  • If sexually active, willing to use two acceptable methods of during and for 4 weeks after the study

    • Males post vasectomy for 2 years with no known pregnancies do not need to use any other forms of contraception during the study.
    • Females who have been in menopause for at least 2 years, have had a tubal ligation at least 1 year prior to screening, or have had a total hysterectomy do not need to use any other forms of contraception during the study.
  • Have received documented approval from a study dietitian confirming that the subject is capable of maintaining their diet
  • Have neurocognitive and linguistic capacities to comprehend and answer investigator's prompts for the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) Investigator rated instrument and to complete the POMS-Subject rated scale
  • If applicable, maintained stable dose of medication for Attention Deficit Hyperactivity Disorder (ADHD), depression, anxiety, or other psychiatric disorder ≥8 weeks prior to enrollment and willing to maintain stable dose throughout study unless a change is medically indicated
  • General good health, as evidenced by physical examination, clinical laboratory evaluations, and tests at screening

Exclusion criteria

Exclusion Criteria

Individuals who meet any of the following exclusion criteria will not be eligible to participate in the study:

  • Use of any product (except BMN 165) or investigational medical device within 30 days prior to screening or requirement for any investigational agent prior to completion of all scheduled study assessments
  • Use of any medication (except BMN 165) intended to treat PKU, including the use of large neutral amino acids, within 2 days prior to the administration of study drug
  • Have known to Dextran® or components of Dextran
  • Use or planned use of any injectable drugs containing PEG (except for BMN 165), including medroxyprogesterone injection, within 3 months prior to screening and during study participation
  • Current use of levodopa
  • A positive test for antibody, surface antigen, or antibody
  • A history of organ transplantation or taking chronic therapy
  • A history of substance abuse in the past 12 months or current alcohol or drug abuse
  • Current participation in the Kuvan registry study (PKUDOS). Patients may discontinue the PKUDOS registry trial to allow enrollment in this study
  • Pregnant or breastfeeding at screening or planning to become pregnant (self or partner) or breastfeed at any time during the study
  • Concurrent disease or condition that would interfere with study participation or safety.
  • Major surgery planned during the study period
  • Any condition that in the view of the investigator, places the subject at high risk of poor treatment compliance or terminating early from the study
  • (ALT) concentration at least 2x the
  • Creatinine at least 1.5x the upper limit of normal
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
215 participants (actual)

Study arms

  • Active comparator
    BMN165 20mg/day

    BMN165 20mg/day self-administered daily

    Drug: BMN165 20mg/day

  • Placebo comparator
    20 mg/day Placebo

    20 mg/day Placebo self-administered daily

    Drug: Placebo

  • Active comparator
    BMN165 40mg/day

    BMN165 40mg/day self-administered daily

    Drug: BMN165 40mg/day

  • Placebo comparator
    40 mg/day Placebo

    40 mg/day Placebo self-administered daily

    Drug: Placebo

Interventions

  • DrugBMN165 20mg/day

    Drug page: Pegvaliase

    BMN165 20mg/day self-administered daily

    Also known as: PEG-PAL

  • DrugBMN165 40mg/day

    Drug page: Pegvaliase

    BMN165 40mg/day self-administered daily

    Also known as: PEG-PAL

  • DrugPlacebo

    Non-drug placebo, self-administered daily

    Also known as: Dextran 40

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Blood Plasma Phenylalanine (Phe) Concentration at Part 2

    Blood phe concentration in subjects previously exposed to BMN165 who were administered BMN165 20 or 40 mg/day compared with those who were administered a matching placebo.

    Time frame: At Part 2 baseline and change from baseline at Part 2 week 8

Secondary outcomes

  1. Change From Baseline in the Cognitive and Mood Symptoms Measured by ADHD Rating Scale (RS)-IV Inattention Subscale at Part 2

    Attention deficit hyperactivity disorder rating scale IV (ADHD RS-IV) is investigator-rated, 9-item, inattention subscale score ranges from 0 to 27, with higher scores indicative of a greater degree of impairment and a baseline score \>9 indicative of a presence of symptoms.

    Time frame: At Part 2 baseline and change from baseline at Part 2 week 8

  2. Change From Baseline in the Blood Plasma Phenylalanine (Phe) Concentration at Part 4

    The long term effect of multiple dose levels of BMN165 on blood phe concentration in subjects who are administered BMN165 using pre-filled syringes.

    Time frame: At Part 4 week 57, 105, 161, 209 and 249

  3. Change From Baseline in the Cognitive and Mood Symptoms Measured by PKU POMS TMD at Part 2

    Phenylketonuria (PKU) Total Mood Disturbance (TMD) Profile of Mood States (POMS) PKU POMS TMD is self-rated, each item in the tool is rated using a five-point Likert scale: 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a bit), and 4 (extremely).

    Time frame: At Part 2 baseline and change from baseline at Part 2 week 8

  4. Change From Baseline in the Cognitive and Mood Symptoms Measured by PKU POMS Confusion Subscale at Part 2

    PKU POMS confusion mood domain (referred to as the confusion subscale) is self-rated, each item in the tool is rated using a five-point Likert scale: 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a bit), and 4 (extremely).

    Time frame: At Part 2 baseline and change from baseline at Part 2 week 8

  5. Change From Baseline in the Cognitive and Mood Symptoms Measured by POMS TMD at Part 2

    Full-length POMS TMD is self-rated, each item in the tool is rated using a five-point Likert scale: 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a bit), and 4 (extremely).

    Time frame: At Part 2 baseline and change from baseline at Part 2 week 8

07

Results

Posted Jul 12, 2019

Participant flow

This was a multicenter study, conducted in 29 study centers of United States.

Part 1 (Up to 13 Weeks)
Participant flow — Part 1 (Up to 13 Weeks)
MilestoneBMN165 20mg/DayPlacebo 20mg/DayBMN165 40mg/DayPlacebo 40mg/DayBMN165
Started8607800
Completed7407800
Not completed120000
Withdrew: Adverse event40000
Withdrew: Withdrawal by subject20000
Withdrew: Lost to follow-up40000
Withdrew: Physician decision20000
Part 2 (8 Weeks)
Participant flow — Part 2 (8 Weeks)
MilestoneBMN165 20mg/DayPlacebo 20mg/DayBMN165 40mg/DayPlacebo 40mg/DayBMN165
Started341532140
Per amendment #2 of the protocol291429140
Completed341531140
Not completed00100
Withdrew: Withdrawal by subject00100
Part 3A/B (6 Week)
Participant flow — Part 3A/B (6 Week)
MilestoneBMN165 20mg/DayPlacebo 20mg/DayBMN165 40mg/DayPlacebo 40mg/DayBMN165
Started4804100
Per amendment #2 of the protocol3402600
Completed4804100
Not completed00000
Part 4 (Up to 274 Weeks)
Participant flow — Part 4 (Up to 274 Weeks)
MilestoneBMN165 20mg/DayPlacebo 20mg/DayBMN165 40mg/DayPlacebo 40mg/DayBMN165
Started0000202
Completed0000172
Not completed000030
Withdrew: Adverse event00005
Withdrew: Subject withdrew consent000014
Withdrew: Lost to follow-up00004
Withdrew: Physician decision00005
Withdrew: Protocol deviations00002

Outcome measures

PrimaryChange From Baseline in the Blood Plasma Phenylalanine (Phe) Concentration at Part 2

Blood phe concentration in subjects previously exposed to BMN165 who were administered BMN165 20 or 40 mg/day compared with those who were administered a matching placebo.

Time frame:
At Part 2 baseline and change from baseline at Part 2 week 8
Reported as:
Mean · µmol/L
Change From Baseline in the Blood Plasma Phenylalanine (Phe) Concentration at Part 2
µmol/LBMN165 20mg/DayPlacebo 20mg/DayBMN165 40mg/DayPlacebo 40mg/Day
Part 2 Baseline596.8 ± 582.75563.9 ± 504.62410.9 ± 439.95508.2 ± 363.68
Change from Baseline Part 2 Week 8-65.9 ± 192.02996.4 ± 555.00114.1 ± 332.40599.0 ± 507.40
Statistical analysis
  • BMN165 20mg/Day vs Placebo 20mg/Day · ANCOVA · p = <0.0001 (Based on Mixed-Effect Model Repeated Measure (MMRM) model with change from baseline as the response variable, and treatment, visit and treatment by visit interaction and baseline blood phe concentration as factors.) · Mean difference (net): -973.02 · 95% CI -1204.19 to -741.85
  • BMN165 40mg/Day vs Placebo 40mg/Day · ANCOVA · p = <0.0001 (Based on Mixed-Effect Model Repeated Measure (MMRM) model with change from baseline as the response variable, and treatment, visit and treatment by visit interaction and baseline blood phe concentration as factors.) · Mean difference (net): -588.50 · 95% CI -830.07 to -346.94
SecondaryChange From Baseline in the Cognitive and Mood Symptoms Measured by ADHD Rating Scale (RS)-IV Inattention Subscale at Part 2

Attention deficit hyperactivity disorder rating scale IV (ADHD RS-IV) is investigator-rated, 9-item, inattention subscale score ranges from 0 to 27, with higher scores indicative of a greater degree of impairment and a baseline score \>9 indicative of a presence of symptoms.

Time frame:
At Part 2 baseline and change from baseline at Part 2 week 8
Reported as:
Mean · Units on a scale
Change From Baseline in the Cognitive and Mood Symptoms Measured by ADHD Rating Scale (RS)-IV Inattention Subscale at Part 2
Units on a scaleBMN165 20mg/DayPlacebo 20mg/DayBMN165 40mg/DayPlacebo 40mg/Day
Baseline5.9 ± 4.705.0 ± 4.266.0 ± 6.452.9 ± 3.68
Change from Baseline Part 2 Week 81.1 ± 3.961.2 ± 3.000.5 ± 5.36-0.4 ± 3.44
SecondaryChange From Baseline in the Blood Plasma Phenylalanine (Phe) Concentration at Part 4

The long term effect of multiple dose levels of BMN165 on blood phe concentration in subjects who are administered BMN165 using pre-filled syringes.

Time frame:
At Part 4 week 57, 105, 161, 209 and 249
Reported as:
Mean · µmol/L
Change From Baseline in the Blood Plasma Phenylalanine (Phe) Concentration at Part 4
µmol/LBMN165 < 20 mg/Day - Part 4BMN165 20 to < 40 mg/Day - Part 4BMN165 40 to < 60 mg/Day - Part 4BMN165 >= 60 mg/Day - Part 4BMN165 All Dose - Part 4
Change from Baseline to Part 4 Week 57-1004.9 ± 541.19-984.0 ± 531.33-810.2 ± 595.24-662.3 ± 465.61-839.5 ± 562.74
Change from Baseline to Part 4 Week 105-1015.3 ± 557.00-1109.2 ± 474.25-858.5 ± 593.73-641.0 ± 568.67-890.8 ± 578.38
Change from Baseline to Part 4 Week 161-1006.5 ± 514.76-1111.9 ± 519.40-662.8 ± 433.80-808.6 ± 558.22-882.0 ± 528.61
Change from Baseline to Part 4 Week 209-897.3 ± 494.41-1020.4 ± 495.79-541.6 ± 245.83-961.7 ± 339.92-842.3 ± 418.37
Change from Baseline to Part 4 Week 249-1059.5 ± 160.51——-1314.0 ± NA-1144.3 ± 185.67
SecondaryChange From Baseline in the Cognitive and Mood Symptoms Measured by PKU POMS TMD at Part 2

Phenylketonuria (PKU) Total Mood Disturbance (TMD) Profile of Mood States (POMS) PKU POMS TMD is self-rated, each item in the tool is rated using a five-point Likert scale: 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a bit), and 4 (extremely).

Time frame:
At Part 2 baseline and change from baseline at Part 2 week 8
Reported as:
Mean · Units on a scale
Change From Baseline in the Cognitive and Mood Symptoms Measured by PKU POMS TMD at Part 2
Units on a scaleBMN165 20mg/DayPlacebo 20mg/DayBMN165 40mg/DayPlacebo 40mg/Day
Baseline7.1 ± 14.188.6 ± 10.848.9 ± 12.285.0 ± 8.56
Change from Baseline Part 2 Week 84.8 ± 12.634.3 ± 11.96-2.0 ± 10.250.0 ± 14.08
SecondaryChange From Baseline in the Cognitive and Mood Symptoms Measured by PKU POMS Confusion Subscale at Part 2

PKU POMS confusion mood domain (referred to as the confusion subscale) is self-rated, each item in the tool is rated using a five-point Likert scale: 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a bit), and 4 (extremely).

Time frame:
At Part 2 baseline and change from baseline at Part 2 week 8
Reported as:
Mean · Units on a scale
Change From Baseline in the Cognitive and Mood Symptoms Measured by PKU POMS Confusion Subscale at Part 2
Units on a scaleBMN165 20mg/DayPlacebo 20mg/DayBMN165 40mg/DayPlacebo 40mg/Day
Baseline2.0 ± 2.092.1 ± 1.492.4 ± 2.021.2 ± 1.53
Change from Baseline Part 2 Week 80.8 ± 2.791.4 ± 2.47-0.3 ± 1.840.5 ± 2.22
SecondaryChange From Baseline in the Cognitive and Mood Symptoms Measured by POMS TMD at Part 2

Full-length POMS TMD is self-rated, each item in the tool is rated using a five-point Likert scale: 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a bit), and 4 (extremely).

Time frame:
At Part 2 baseline and change from baseline at Part 2 week 8
Reported as:
Mean · Units on a scale
Change From Baseline in the Cognitive and Mood Symptoms Measured by POMS TMD at Part 2
Units on a scaleBMN165 20mg/DayPlacebo 20mg/DayBMN165 40mg/DayPlacebo 40mg/Day
Baseline16.2 ± 35.6318.1 ± 28.2624.3 ± 35.3813.3 ± 21.63
Change from Baseline Part 2 Week 813.1 ± 30.737.3 ± 26.23-3.2 ± 26.63-1.7 ± 29.34

Adverse events

Collected over Up to 301 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 - 20 mg/Day0/86 (0%)6/86 (7%)70/86 (81.4%)
Part 1 - 40 mg/Day0/78 (0%)2/78 (2.6%)59/78 (75.6%)
Part 2 - 20 mg/Day Active0/34 (0%)0/34 (0%)27/34 (79.4%)
Part 2 - 40 mg/Day Active0/32 (0%)2/32 (6.3%)28/32 (87.5%)
Part 2 - 20 mg/Day Placebo0/15 (0%)1/15 (6.7%)14/15 (93.3%)
Part 2 - 40 mg/Day Placebo0/14 (0%)0/14 (0%)13/14 (92.9%)
Part 3 - Stay on Active 20 mg/Day0/23 (0%)1/23 (4.3%)19/23 (82.6%)
Part 3 - Stay on Active 40 mg/Day0/18 (0%)0/18 (0%)15/18 (83.3%)
Part 3 - Switch From Placebo to Active 20 mg/Day0/11 (0%)0/11 (0%)8/11 (72.7%)
Part 3 - Switch From Placebo to Active 40 mg/Day0/8 (0%)0/8 (0%)7/8 (87.5%)
Part 4 - < 20 mg/Day0/67 (0%)7/67 (10.4%)62/67 (92.5%)
Part 4 - 20 to < 40 mg/Day0/152 (0%)6/152 (3.9%)105/152 (69.1%)
Part 4 - 40 to < 60 mg/Day0/186 (0%)16/186 (8.6%)178/186 (95.7%)
Part 4 - >= 60 mg/Day0/89 (0%)5/89 (5.6%)59/89 (66.3%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventPart 1 - 20 mg/DayPart 1 - 40 mg/DayPart 2 - 20 mg/Day ActivePart 2 - 40 mg/Day ActivePart 2 - 20 mg/Day PlaceboPart 2 - 40 mg/Day PlaceboPart 3 - Stay on Active 20 mg/DayPart 3 - Stay on Active 40 mg/DayPart 3 - Switch From Placebo to Active 20 mg/DayPart 3 - Switch From Placebo to Active 40 mg/DayPart 4 - < 20 mg/DayPart 4 - 20 to < 40 mg/DayPart 4 - 40 to < 60 mg/DayPart 4 - >= 60 mg/Day
Blood creatine phosphokinase increasedInvestigations0/860/780/340/321/150/141/230/180/110/81/670/1520/1860/89
AgitationPsychiatric disorders0/860/780/341/320/150/140/230/180/110/80/670/1520/1860/89
DepressionPsychiatric disorders0/860/780/341/320/150/140/230/180/110/80/671/1520/1860/89
Road Traffic AccidentInjury, poisoning and procedural complications0/861/780/340/320/150/140/230/180/110/82/670/1520/1860/89
Anaphylactic ReactionImmune system disorders0/860/780/340/320/150/140/230/180/110/80/671/1524/1860/89
Blood pressure increasedInvestigations0/860/780/340/320/150/140/230/180/110/81/670/1520/1860/89
Abortion missedPregnancy, puerperium and perinatal conditions0/860/780/340/320/150/140/230/180/110/81/670/1520/1860/89
Gestational hypertensionPregnancy, puerperium and perinatal conditions0/860/780/340/320/150/140/230/180/110/81/670/1520/1860/89
EndometriosisReproductive system and breast disorders0/860/780/340/320/150/140/230/180/110/81/670/1520/1860/89
HypersensitivityImmune system disorders0/861/780/340/320/150/140/230/180/110/80/671/1522/1860/89
Most frequent other events
Showing 10 of 123
Most frequent other events
EventPart 1 - 20 mg/DayPart 1 - 40 mg/DayPart 2 - 20 mg/Day ActivePart 2 - 40 mg/Day ActivePart 2 - 20 mg/Day PlaceboPart 2 - 40 mg/Day PlaceboPart 3 - Stay on Active 20 mg/DayPart 3 - Stay on Active 40 mg/DayPart 3 - Switch From Placebo to Active 20 mg/DayPart 3 - Switch From Placebo to Active 40 mg/DayPart 4 - < 20 mg/DayPart 4 - 20 to < 40 mg/DayPart 4 - 40 to < 60 mg/DayPart 4 - >= 60 mg/Day
ArthralgiaMusculoskeletal and connective tissue disorders9/8613/787/342/321/152/143/230/183/112/816/6733/15264/18622/89
NasopharyngitisInfections and infestations7/8611/784/341/320/151/142/230/180/110/815/6727/15259/18619/89
HeadacheNervous system disorders16/8612/786/342/323/154/142/233/181/110/820/6729/15259/18624/89
Upper respiratory tract infectionInfections and infestations8/865/781/340/323/152/143/232/181/110/814/6729/15251/18610/89
Injection site reactionGeneral disorders13/867/784/341/321/151/143/231/181/110/86/6714/15246/18611/89
FatigueGeneral disorders8/863/784/343/323/150/145/234/180/111/810/678/15214/18610/89
Injection site bruisingGeneral disorders9/867/782/341/322/151/142/231/180/110/85/6714/15241/18612/89
Nasal congestionRespiratory, thoracic and mediastinal disorders4/862/781/340/323/150/140/230/181/110/89/6712/15220/1868/89
Amino acid level decreasedInvestigations3/861/780/340/320/150/140/231/180/110/89/6713/15237/18613/89
RashSkin and subcutaneous tissue disorders2/866/782/343/321/150/142/232/180/111/87/678/15234/18614/89

Baseline characteristics

All Subjects consists of subjects participated in 165-302 Part 1, 2, 3 and 4.

Age, Continuous
Age, Continuous(yrs)All Subjects
Mean29.22 ± 8.74
Age, Customized
Age, Customized(Participants)All Subjects
16 - <18 years11
18 - <66 years204
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female105
Male110
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Subjects
American Indian or Alaska Native1
White211
Black/African American2
08

Study locations

29 sites
  • University of California, San Diego Clinical and Translational Research Institute
    La Jolla, California 92093, United States
  • UCSF Benioff Children's Hospital Oakland
    Oakland, California 94609, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • University of Florida Clinical Research Center
    Gainesville, Florida 32610, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Emory Universty, Department of Human Genetics, Division of Medical Genetics
    Atlanta, Georgia 30322, United States
  • Ann and Robert H Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Indiana CTSI Clinical Research Center
    Indianapolis, Indiana 46202, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
  • University of Louisville, Kosair Charities Pediatric Clinical Research Unit
    Louisville, Kentucky 40202, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Wayne State University Clinical Research Center at the Mott Center
    Detroit, Michigan 48202, United States
  • University of Missouri Health Center
    Columbia, Missouri 65212, United States
  • Washington University Center for Applied Research Sciences
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Cooper Health Systems
    Camden, New Jersey 08103, United States
  • Atlantic Health System - Morristown Medical Center
    Morristown, New Jersey 07960, United States
  • Albany Medical Center
    Albany, New York 12208, United States
  • Icahn School of Medicine at Mount Sinai Medical Center
    New York, New York 10029, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • St. Christopher's Hospital for Children
    Philadelphia, Pennsylvania 19134, United States
  • Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15224, United States
  • Vanderbilt Children's Hospital
    Nashville, Tennessee 37232, United States
  • University of Texas Houston Medical School
    Houston, Texas 77030, United States
  • University of Utah Hospital
    Salt Lake City, Utah 84108, United States
  • University of Washinton
    Seattle, Washington 98195, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Bilder DA, Arnold GL, Dimmock D, Grant ML, Janzen D, Longo N, Nguyen-Driver M, Jurecki E, Merilainen M, Amato G, Waisbren S. Improved attention linked to sustained phenylalanine reduction in adults with early-treated phenylketonuria. Am J Med Genet A. 2022 Mar;188(3):768-778. doi: 10.1002/ajmg.a.62574. Epub 2021 Nov 26. PubMed 34826353 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2013 to primary completion in Jan 2016, 29 months.

Results were first posted in Jul 2019, 3 years 5 months after primary completion. A results delay was requested in Dec 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2013
First posted
Jul 1, 2013
StartActual
Jul 29, 2013
Primary completionActual
Jan 13, 2016
CompletionActual
Feb 5, 2019
Results delay requested
Dec 22, 2017
Results first posted
Jul 12, 2019
Last update
May 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01889862
Responsible party
Sponsor
First posted
Jul 1, 2013
Start date
Jul 29, 2013
Primary completion
Jan 13, 2016
Completion
Feb 5, 2019
Results posted
Jul 12, 2019
Last update
May 21, 2021

Study contacts

Clinical Trial Specialist
study director · BioMarin Pharmaceutical

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegvaliase

Start the discussion